Welcome to our dedicated page for Amicus Therapeut SEC filings (Ticker: FOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking gene-therapy progress across hundreds of pages can feel overwhelming, especially when Amicus Therapeutics packs each report with dense clinical data, orphan-drug milestones, and complex risk factors. If you have ever searched for “Amicus Therapeutics insider trading Form 4 transactions” or wondered where the Fabry trial costs sit in the latest 10-Q, you know the challenge.
Stock Titan solves it. Our AI reads every Amicus Therapeutics quarterly earnings report 10-Q filing, parses R&D expense lines, and links them to pipeline stages—turning raw numbers into plain-English insights. Receive real-time alerts the moment a director files a “Amicus Therapeutics Form 4 insider transactions real-time” notice. Need context? Our summaries place each disclosure next to prior periods so you instantly see trends. From the Amicus Therapeutics annual report 10-K simplified that explains cash runway, to an “Amicus Therapeutics 8-K material events explained” note covering fresh FDA guidance, every document is indexed, searchable, and annotated.
Use cases include: spotting executive stock sales via “Amicus Therapeutics executive stock transactions Form 4”; comparing quarter-over-quarter revenue with our “Amicus Therapeutics earnings report filing analysis”; or reviewing “Amicus Therapeutics proxy statement executive compensation” to gauge incentive alignment. Whether you are understanding Amicus Therapeutics SEC documents with AI for the first time or maintaining a hedge-fund model, our platform delivers complete, up-to-the-minute coverage—no biomedical PhD required.
Sleep Number (SNBR) Q2 2025 10-Q highlights: Net sales fell 20% YoY to $327.9 million as retail comparable sales declined 19% and store count dropped to 630. Six-month sales decreased 18% to $721.2 million. Gross margin held at 59.1%, benefiting from 140 bp of product-cost savings offset by unfavorable mix and higher warranty/return costs.
Operating loss was $0.1 million (vs. $6.1 million profit LY) after $8.3 million of restructuring charges. Net loss widened to $25.0 million ($1.09 per diluted share); YTD loss is $33.7 million. Adjusted EBITDA slipped to $23.6 million from $28.3 million.
Cost-reduction program has generated $42.2 million cumulative charges and projects another ~$8 million in 2H 2025. Operating expenses were $42 million lower YoY, driven by 32% cut in media spend and lower incentive comp.
Balance sheet & liquidity: Cash was just $1.3 million; free cash flow burned $6.9 million YTD. Revolver borrowings rose to $563.9 million (7.9% weighted-avg rate), pushing leverage to 4.6×—just below the amended 4.75× covenant. The March 2025 credit amendment introduced a minimum $40 million liquidity covenant and step-down leverage/coverage targets through 2026; company remains compliant with $102 million revolver availability.
Outlook risks: sustained demand weakness in a multi-year mattress downturn, elevated interest costs, valuation allowance adding $14 million tax expense, further restructuring outlays, and pending California class-action litigation. Management is prioritizing margin initiatives, cash generation, and reduced capex ($8 million YTD) while evaluating impact of the newly enacted OBBBA tax law.
FAQ
What is the current stock price of Amicus Therapeut (FOLD)?
What is the market cap of Amicus Therapeut (FOLD)?
What is the core focus of Amicus Therapeutics Inc?
How does Amicus Therapeutics generate revenue?
Which therapeutic areas are prioritized by Amicus Therapeutics?
How does the company differentiate itself in the competitive biotech landscape?
What types of products does Amicus Therapeutics develop?
How does Amicus Therapeutics ensure scientific and clinical excellence?
What are some challenges faced by companies in the rare disease sector?
How does Amicus Therapeutics contribute to patient care beyond drug development?
